Top 5 Key Takeaways from ASCO 2018

Article
Conference|American Society of Clinical Oncology

The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, Illinois, June 1-5, 2018, featured data from numerous studies and advancements being made in rare cancers. Here are 5 key takeaways from the meeting.

The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, Illinois, June 1-5, 2018, featured data from numerous studies and advancements being made in rare cancers. Here are 5 key takeaways from the meeting.

Related Videos
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
Ghada Bourjeily, MD: Research Gaps on Sleep Issues During Pregnancy
John Winkelman, MD, PhD: When to Use Low-Dose Opioids for Restless Legs Syndrome
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Related Content
Risk of Malignancy, Major Adverse Cardiovascular Events in Patients with Atopic Dermatitis

Risk of Malignancy, Major Adverse Cardiovascular Events in Patients with Atopic Dermatitis

Tim Smith
June 14th 2024
Article
Javed Butler, MD | Credit: BAIM Institute

Don't Miss a Beat: EMPACT-MI at ACC.24, with Javed Butler, MD

Muthiah Vaduganathan, MD, MPH;Stephen Greene, MD
April 6th 2024
Podcast
James Galloway, MBChB | Credit: Galapagos Health

Certolizumab Pegol Offers Consistent Benefit, Regardless of Rheumatoid Factor Levels

Patrick Campbell
June 14th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: ATTD 2024 Preview

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
February 27th 2024
Podcast
Upadacitinib Led to Sustained, 140-Week Improvements for Atopic Dermatitis Patients

Upadacitinib Led to Sustained, 140-Week Improvements for Atopic Dermatitis Patients

Tim Smith
June 13th 2024
Article
Bimekizumab Response is Sustained Over 4 Years in Plaque Psoriasis

Bimekizumab Response is Sustained Over 4 Years in Plaque Psoriasis

Lana Pine
June 13th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.